Posted: July 29, 2024 at 2:33 am
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive of its potential for target engagement in Alzheimer’s disease patients
Read the rest here:
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
Posted: July 29, 2024 at 2:33 am
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial.
Posted: July 29, 2024 at 2:33 am
SHANGHAI, July 26, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary TopAlliance Biosciences Inc. (TopAlliance Biosciences), announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for the marketing authorization application (MAA) for toripalimab (European trade name: LOQTORZI®). The CHMP recommends approval for toripalimab for two indications:
Original post:
Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
Posted: July 29, 2024 at 2:33 am
BOSTON, July 26, 2024 (GLOBE NEWSWIRE) -- eLabNext, a leading provider of digital lab management solutions, and ABI-LAB, a premier life sciences incubator located in Natick, MA, have announced a strategic alliance aimed at driving innovation and supporting the growth of life sciences startups.
Read more:
eLabNext and ABI-LAB Announce Strategic Partnership to Foster Innovation in Life Sciences
Posted: July 29, 2024 at 2:33 am
Company to host conference call on Monday, July 29 at 8:30 a.m. ET Company to host conference call on Monday, July 29 at 8:30 a.m. ET
See the original post here:
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous...
Posted: July 29, 2024 at 2:33 am
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes. Cadisegliatin is an oral, liver selective, glucokinase activator that has been well-tolerated in over 500 subjects to date with up to six months of treatment.
Excerpt from:
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
Posted: July 29, 2024 at 2:32 am
All dollar amounts reflected in Canadian dollars unless otherwise stated. All dollar amounts reflected in Canadian dollars unless otherwise stated.
The rest is here:
Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement
Posted: July 29, 2024 at 2:32 am
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A?Os) for the treatment of Alzheimer’s disease (AD), today announced new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193). The research highlights the experiences of patients in the clinical trial to inform development of future trials, biomarker data to support sabirnetug’s mechanism of action, and an ultra-sensitive method of measuring small amounts of sabirnetug in cerebrospinal fluid (CSF). The posters will be presented at the Alzheimer’s Association International Conference (AAIC®) 2024 taking place in Philadelphia and online from July 28-Aug. 1, 2024.
Read the original:
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International...
Posted: July 29, 2024 at 2:32 am
Wnt-activated, autologous, expanded, adipose-derived stem cells administered directly into lateral ventricles of the brain via Ommaya reservoir implanted under the scalp to bypass blood brain barrier
Posted: July 29, 2024 at 2:32 am
– Featured Research Session oral presentation highlights findings that show Lomecel-B™ improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s Disease –
